Dupont Capital Management Corp Insmed Inc Transaction History

Dupont Capital Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$20.42 - $28.13 $18,868 - $25,992	-924 Reduced 8.13%	10,442 $245,000
Q4 2021 Jan 31, 2022	BUY	$25.89 - $33.45 $50,407 - $65,127	1,947 Added 20.67%	11,366 $310,000
Q3 2021 Nov 03, 2021	SELL	$22.46 - $29.47 $29,916 - $39,254	-1,332 Reduced 12.39%	9,419 $259,000
Q1 2021 Apr 29, 2021	BUY	$32.28 - $44.3 $68,433 - $93,916	2,120 Added 24.56%	10,751 $366,000
Q4 2020 Jan 28, 2021	SELL	$31.45 - $40.54 $20,285 - $26,148	-645 Reduced 6.95%	8,631 $287,000
Q3 2020 Oct 29, 2020	SELL	$26.0 - $34.5 $16,172 - $21,459	-622 Reduced 6.28%	9,276 $298,000
Q2 2020 Jul 24, 2020	BUY	$14.11 - $29.42 $139,660 - $291,199	9,898 New	9,898 $273,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.48B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.